vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and SPX Technologies, Inc. (SPXC). Click either name above to swap in a different company.

Charles River Laboratories is the larger business by last-quarter revenue ($994.2M vs $566.8M, roughly 1.8× SPX Technologies, Inc.). SPX Technologies, Inc. runs the higher net margin — 10.6% vs -27.8%, a 38.4% gap on every dollar of revenue. On growth, SPX Technologies, Inc. posted the faster year-over-year revenue change (22.0% vs -0.8%). Charles River Laboratories produced more free cash flow last quarter ($58.6M vs $11.3M). Over the past eight quarters, SPX Technologies, Inc.'s revenue compounded faster (6.3% CAGR vs -0.9%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

SPX Technologies, Inc. is an American manufacturing company, headquartered in Charlotte, North Carolina. The company operates within four markets: heating, ventilation, and air conditioning (HVAC), detection and measurement, power transmission and generation, and engineered solutions. Examples of SPX’s products include cooling towers and boilers, underground pipe and cable locators, power transformers, and heat exchangers. Brands include Waukesha, Dielectric, Genfare, Fahrenheat, Radiodetecti...

CRL vs SPXC — Head-to-Head

Bigger by revenue
CRL
CRL
1.8× larger
CRL
$994.2M
$566.8M
SPXC
Growing faster (revenue YoY)
SPXC
SPXC
+22.8% gap
SPXC
22.0%
-0.8%
CRL
Higher net margin
SPXC
SPXC
38.4% more per $
SPXC
10.6%
-27.8%
CRL
More free cash flow
CRL
CRL
$47.3M more FCF
CRL
$58.6M
$11.3M
SPXC
Faster 2-yr revenue CAGR
SPXC
SPXC
Annualised
SPXC
6.3%
-0.9%
CRL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CRL
CRL
SPXC
SPXC
Revenue
$994.2M
$566.8M
Net Profit
$-276.6M
$59.9M
Gross Margin
Operating Margin
-28.5%
15.5%
Net Margin
-27.8%
10.6%
Revenue YoY
-0.8%
22.0%
Net Profit YoY
-28.9%
17.0%
EPS (diluted)
$-5.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
SPXC
SPXC
Q1 26
$566.8M
Q4 25
$994.2M
$637.3M
Q3 25
$1.0B
$592.8M
Q2 25
$1.0B
$552.4M
Q1 25
$984.2M
$482.6M
Q4 24
$1.0B
$533.7M
Q3 24
$1.0B
$483.7M
Q2 24
$1.0B
$501.3M
Net Profit
CRL
CRL
SPXC
SPXC
Q1 26
$59.9M
Q4 25
$-276.6M
$77.9M
Q3 25
$54.4M
$62.7M
Q2 25
$52.3M
$52.2M
Q1 25
$25.5M
$51.2M
Q4 24
$-214.5M
$57.1M
Q3 24
$69.7M
$50.2M
Q2 24
$94.1M
$44.2M
Gross Margin
CRL
CRL
SPXC
SPXC
Q1 26
Q4 25
39.8%
Q3 25
40.4%
Q2 25
41.4%
Q1 25
40.6%
Q4 24
40.9%
Q3 24
34.6%
40.9%
Q2 24
34.5%
40.1%
Operating Margin
CRL
CRL
SPXC
SPXC
Q1 26
15.5%
Q4 25
-28.5%
15.7%
Q3 25
13.3%
16.4%
Q2 25
9.7%
15.7%
Q1 25
7.6%
13.8%
Q4 24
-16.7%
16.9%
Q3 24
11.6%
16.3%
Q2 24
14.8%
14.9%
Net Margin
CRL
CRL
SPXC
SPXC
Q1 26
10.6%
Q4 25
-27.8%
12.2%
Q3 25
5.4%
10.6%
Q2 25
5.1%
9.4%
Q1 25
2.6%
10.6%
Q4 24
-21.4%
10.7%
Q3 24
6.9%
10.4%
Q2 24
9.2%
8.8%
EPS (diluted)
CRL
CRL
SPXC
SPXC
Q1 26
Q4 25
$-5.57
$1.56
Q3 25
$1.10
$1.28
Q2 25
$1.06
$1.10
Q1 25
$0.50
$1.09
Q4 24
$-4.17
$1.21
Q3 24
$1.33
$1.06
Q2 24
$1.74
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
SPXC
SPXC
Cash + ST InvestmentsLiquidity on hand
$213.8M
$156.5M
Total DebtLower is stronger
$2.1B
$667.3M
Stockholders' EquityBook value
$3.2B
$2.3B
Total Assets
$7.1B
$3.9B
Debt / EquityLower = less leverage
0.68×
0.29×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
SPXC
SPXC
Q1 26
$156.5M
Q4 25
$213.8M
$364.0M
Q3 25
$207.1M
$229.4M
Q2 25
$182.8M
$132.8M
Q1 25
$229.4M
$177.8M
Q4 24
$194.6M
$156.9M
Q3 24
$210.2M
$124.8M
Q2 24
$179.2M
$128.1M
Total Debt
CRL
CRL
SPXC
SPXC
Q1 26
$667.3M
Q4 25
$2.1B
$496.7M
Q3 25
$2.2B
$499.8M
Q2 25
$2.3B
$950.3M
Q1 25
$2.5B
$872.0M
Q4 24
$2.2B
$577.0M
Q3 24
$2.3B
$665.2M
Q2 24
$2.4B
$509.9M
Stockholders' Equity
CRL
CRL
SPXC
SPXC
Q1 26
$2.3B
Q4 25
$3.2B
$2.2B
Q3 25
$3.4B
$2.1B
Q2 25
$3.4B
$1.5B
Q1 25
$3.2B
$1.4B
Q4 24
$3.5B
$1.4B
Q3 24
$3.8B
$1.4B
Q2 24
$3.7B
$1.3B
Total Assets
CRL
CRL
SPXC
SPXC
Q1 26
$3.9B
Q4 25
$7.1B
$3.6B
Q3 25
$7.5B
$3.4B
Q2 25
$7.6B
$3.3B
Q1 25
$7.6B
$3.1B
Q4 24
$7.5B
$2.7B
Q3 24
$8.0B
$2.8B
Q2 24
$7.9B
$2.8B
Debt / Equity
CRL
CRL
SPXC
SPXC
Q1 26
0.29×
Q4 25
0.68×
0.22×
Q3 25
0.64×
0.23×
Q2 25
0.70×
0.62×
Q1 25
0.79×
0.60×
Q4 24
0.65×
0.42×
Q3 24
0.62×
0.49×
Q2 24
0.65×
0.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
SPXC
SPXC
Operating Cash FlowLast quarter
$147.5M
Free Cash FlowOCF − Capex
$58.6M
$11.3M
FCF MarginFCF / Revenue
5.9%
2.0%
Capex IntensityCapex / Revenue
8.9%
3.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$518.5M
$268.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
SPXC
SPXC
Q1 26
Q4 25
$147.5M
$195.2M
Q3 25
$213.8M
$106.5M
Q2 25
$204.6M
$42.5M
Q1 25
$171.7M
$-10.9M
Q4 24
$159.4M
$166.5M
Q3 24
$251.8M
$51.4M
Q2 24
$193.5M
$57.5M
Free Cash Flow
CRL
CRL
SPXC
SPXC
Q1 26
$11.3M
Q4 25
$58.6M
$126.7M
Q3 25
$178.2M
$96.1M
Q2 25
$169.3M
$34.8M
Q1 25
$112.4M
$-16.4M
Q4 24
$83.7M
$156.7M
Q3 24
$213.1M
$43.5M
Q2 24
$154.0M
$47.1M
FCF Margin
CRL
CRL
SPXC
SPXC
Q1 26
2.0%
Q4 25
5.9%
19.9%
Q3 25
17.7%
16.2%
Q2 25
16.4%
6.3%
Q1 25
11.4%
-3.4%
Q4 24
8.4%
29.4%
Q3 24
21.1%
9.0%
Q2 24
15.0%
9.4%
Capex Intensity
CRL
CRL
SPXC
SPXC
Q1 26
3.3%
Q4 25
8.9%
10.7%
Q3 25
3.5%
1.8%
Q2 25
3.4%
1.4%
Q1 25
6.0%
1.1%
Q4 24
7.5%
1.8%
Q3 24
3.8%
1.6%
Q2 24
3.8%
2.1%
Cash Conversion
CRL
CRL
SPXC
SPXC
Q1 26
Q4 25
2.51×
Q3 25
3.93×
1.70×
Q2 25
3.91×
0.81×
Q1 25
6.74×
-0.21×
Q4 24
2.92×
Q3 24
3.61×
1.02×
Q2 24
2.06×
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

SPXC
SPXC

Segment breakdown not available.

Related Comparisons